• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Biolase Inc. filed SEC Form 8-K: Bankruptcy or Receivership

    10/1/24 4:05:10 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care
    Get the next $BIOL alert in real time by email
    8-K
    false000081124000008112402024-09-302024-09-30

     

    ‌ UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (date of earliest event reported): September 30, 2024

    BIOLASE, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    001-36385

    87-0442441

    (State or other jurisdiction of incorporation)

    (Commission File No.)

    (IRS Employer Identification No.)

    27042 Towne Centre Drive, Suite 270

    Lake Forest, California 92610

    (Address of principal executive offices) (Zip Code)

    Registrant’s telephone number, including area code: (949) 361-1200

    N/A

    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

     N/A

    N/A

    N/A

    Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.01. Entry into a Material Definitive Agreement.

    The information set forth below under Item 1.03 of this Current Report on Form 8-K regarding the Asset Purchase Agreement (as defined below) is incorporated by reference herein.

    Item 1.03. Bankruptcy or Receivership.

    Voluntary Petitions for Bankruptcy

    On October 1, 2024, BIOLASE, Inc. (the “Company”) and its direct domestic subsidiaries (together with the Company, the “Debtors”) filed voluntary petitions for relief (the “Bankruptcy Petitions”) under chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). The Debtors will continue to operate their businesses as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. The Debtors filed with the Bankruptcy Court various “first day” motions, requesting customary relief that will enable them to transition into chapter 11 and uphold their commitments to stakeholders during the process without material disruption to their ordinary course operations.

    Additionally, the Debtors filed with the Bankruptcy Court a motion seeking approval of certain procedures relating to the marketing and auction (if necessary) of all or some of the Company’s assets, including approval of the Asset Purchase Agreement and the Bidding Procedures (as defined below).

    The Company has engaged SSG Capital Advisors, LLC, to advise on its strategic options, including a potential sale of all or some of the Company’s assets in connection with the Bankruptcy Petitions. Any of those sales would be subject to review and approval by the Bankruptcy Court and compliance with court-approved bidding procedures. The Company cannot be certain that the Company’s securityholders will receive any payment or other distribution on account of their shares following such sales.

    Additional information about the Bankruptcy Petitions, including access to Bankruptcy Court documents, is available online at https://dm.epiq11.com/Biolase, a website administered by Epiq Corporate Restructuring, LLC, a third-party bankruptcy claims and noticing agent. The documents and other information on this website are not part of this Current Report on Form 8-K and shall not be deemed incorporated by reference herein.

    Asset Purchase Agreement

    On September 30, 2024, the Debtors entered into a “stalking horse” asset purchase agreement (the “Asset Purchase Agreement”) with Sonendo, Inc., a Delaware corporation (the “Purchaser”), pursuant to which the Purchaser has agreed to acquire substantially all of the Debtors’ assets (the “Transferred Assets”). The acquisition of the Transferred Assets by the Purchaser pursuant to the Asset Purchase Agreement is subject to approval of the Bankruptcy Court and one or more auctions, if necessary, to solicit higher or otherwise better bids. On October 1, 2024, the Debtors filed a motion (the “Bidding Procedures Motion”) seeking approval of, among other things, certain bidding procedures (the “Bidding Procedures”), which will establish procedures for the selection of the highest or otherwise best bids for the sale of the Transferred Assets and other assets. Other interested bidders would be permitted to participate in the auction if they submit qualifying bids that are higher or otherwise better than the Asset Purchase Agreement. The Asset Purchase Agreement acts as a baseline for competitive bids for the acquisition of the Transferred Assets. The Bidding Procedures Motion additionally seeks the Bankruptcy Court’s approval of the Asset Purchase Agreement and designation of the Purchaser as the “stalking horse” bidder for the Transferred Assets.

    Under the Asset Purchase Agreement, the Purchaser has agreed, subject to the Bankruptcy Court’s approval and absent any higher or otherwise better bid, to acquire the Transferred Assets from the Debtors for (a) $14.0 million in cash paid at closing, subject to a working capital adjustment; plus (b) assumption of certain Assumed Liabilities (as defined in the Asset Purchase Agreement); plus (c) the Delaware Litigation Settlement Value (as defined in the Asset Purchase Agreement). The Asset Purchase Agreement includes customary representations and warranties and various customary covenants under the circumstances that are subject to certain limitations, including, without limitation, a break-up fee, expense reimbursement and the right to designate executory contracts and unexpired leases to assume or reject.


    The foregoing description of the Bidding Procedures and the Asset Purchase Agreement remains subject to approval by the Bankruptcy Court, is not complete, and is qualified in its entirety by reference to the Asset Purchase Agreement, a copy of which is attached as Exhibit 10.1 hereto and is incorporated by reference herein.

    DIP Financing

    In connection with the Bankruptcy Petitions, the Debtors filed a motion seeking Bankruptcy Court approval of a debtor-in-possession financing on the terms set forth in that certain Terms and Conditions of Proposed Senior Secured, Super-Priority Debtor-in-Possession Credit Facility (the “DIP Term Sheet”), by and among the Company, as a borrower, and SWK Funding LLC, as DIP Lender and Agent. The DIP Term Sheet provides for a senior secured super-priority debtor-in-possession financing (the “DIP Financing”) in an aggregate amount of no less than $2.5 million. The DIP Financing will become available up to an amount of $1.43 million upon the satisfaction of customary conditions precedent thereto, including the entry of an order of the Bankruptcy Court approving the DIP Financing on an interim basis. Subject to entry of an order of the Bankruptcy Court approving the DIP Financing on a final basis, the DIP Obligations (as defined in the DIP Term Sheet) will include $2,500,000 advanced by SWK to the Debtors between September 3, 2024, and September 30, 2024.

    The proceeds of the DIP Financing will be used by the Company to (a) fund, after application of all other available cash, post-petition operating expenses and working capital needs of the Company, including, but not limited to, those activities required to remain in, or return to, compliance with laws in accordance with 28 U.S.C. § 1930; (b) pay interest, fees and expenses to SWK in accordance with the DIP Term Sheet (whether or not such amounts are reflected in the Budget (as defined in the DIP Term Sheet)); (c) fund fees and expenses incurred in connection with the 363 Sale (as defined in the DIP Term Sheet); (d) pay permitted prepetition claims and adequate protection payments, if any; (e) pay Professional Fees (as defined in the DIP Term Sheet) provided for in the Budget, including funding of the Carve Out (as defined in the DIP Term Sheet); and (f) pay other costs and expenses of administration of the chapter 11 cases.

    The maturity date of the loans made under the DIP Financing is the date that is one hundred-twenty (120) days after the Petition Date, or such later date to which SWK consents in writing.

    Subject to certain exceptions, the DIP Financing will be secured by a first priority perfected priming security interest in all of the assets of the Company. The security interests and liens are subject only to certain carve-outs and certain permitted liens, as set forth in the DIP Term Sheet. The DIP Financing is subject to certain milestones, customary covenants, and events of default as set forth in the DIP Term Sheet.

    The foregoing description of the DIP Term Sheet is not complete and is qualified in its entirety by reference to the DIP Term Sheet filed with the Bankruptcy Court.

    Item 2.04. Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

    The filing of the Bankruptcy Petitions described in Item 1.03 above constitutes an event of default that accelerates the Company’s obligations under the following agreements: that certain Credit Agreement, dated November 9, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) by and among the Company, the lender parties thereto (each a “Lender” and together, the “Lenders”), and SWK (the “Credit Agreement”); and those certain standard loan documents required for an unsecured loan, dated as of May 22, 2020 (the “SBA Loan”) by and among the Company and the U.S. Small Business Administration(collectively, the “Financial Obligation Agreements”). The Financial Obligation Agreements provide that as a result of the Bankruptcy Petitions described in Item 1.03 above, all obligations to pay any debts, principal, interest, fees, expenses, and other amounts due thereunder shall be immediately due and payable. Any efforts to enforce such payment obligations under the Financial Obligation Agreements are automatically stayed as a result of the Bankruptcy Petitions, and the creditors’ rights of enforcement in respect of the Financial Obligation Agreements are subject to the applicable provisions of the Bankruptcy Code.

    Item 8.01. Other Events.

    On October 1, 2024, the Company issued a press release announcing the filing of the Bankruptcy Petitions. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.


    Cautionary Statements Regarding Trading in the Company’s Securities

    The Company’s securityholders are cautioned that trading in the Company’s securities during the pendency of the Bankruptcy Petitions is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by the Company’s securityholders in the Bankruptcy Petitions. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities. In particular, the Company expects that its securityholders could experience a significant or complete loss on their investment, depending on the outcome of the Bankruptcy Petitions.

    Cautionary Note Regarding Forward-Looking Statements

    This Current Report on Form 8-K and the exhibits hereto contain statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include, but are not limited to, statements about the Company’s plans to sell its assets pursuant to chapter 11 of the Bankruptcy Code; the Company’s expectations regarding the Asset Purchase Agreement and the Bidding Procedures, including the expected amount of proceeds from the transaction; the Company’s intention to continue operations during the Bankruptcy Petitions; the Company’s belief that the 363 sale process will be in the best interest of the Company and its stakeholders; the Company’s expectations regarding the DIP Financing, including the expected amount and use of proceeds from the transaction; and other statements regarding the Company’s strategy and future operations, performance and prospects, among others. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with the potential adverse impact of the Bankruptcy Petitions on the Company’s liquidity and results of operations; changes in the Company’s ability to meet its financial obligations during the Bankruptcy Petitions and to maintain contracts that are critical to its operations; the outcome and timing of the Bankruptcy Petitions and any potential sale of all or some of the Debtors’ assets; the effect of the filing of the Bankruptcy Petitions and any potential sale of all or some of the Debtors’ assets on the Company’s relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the Bankruptcy Petitions or the potential sale of all or some of the Debtors’ assets; uncertainty regarding obtaining the Bankruptcy Court’s approval of the potential sale of all or some of the Debtors’ assets or other conditions to the potential sale of all or some of the Debtors’ assets, or the DIP Financing; any purchase price adjustments to the amount of proceeds pursuant to the Asset Purchase Agreement; the Company’s ability to negotiate definitive documentation for or perform under the terms of the DIP Term Sheet and any other arrangement with lenders or creditors during the chapter 11 cases; the timing or amount of any distributions, if any, to the Company’s stakeholders; and the other factors discussed in the Company’s periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and subsequent reports filed with the SEC. All forward-looking statements are based on information available to the Company as of the date of this Current Report on Form 8-K and the Company undertakes no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    10.1*

    Asset Purchase Agreement dated as of September 30, 2024, by and among BIOLASE, Inc., its subsidiaries named therein, and Sonendo, Inc.

    99.1

    Press Release of BIOLASE, Inc. dated October 1, 2024.

    104

    Cover page Interactive data file (embedded within the inline XBRL document).

     


    * Schedules and attachments have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules and attachments upon request by the Securities and Exchange Commission.

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ‌

     

     

     

     

    ‌

    BIOLASE, INC.

    Date: October 1, 2024

    ‌

    By:

    /s/ John R. Beaver

    ‌

    Name:

    John R. Beaver

    Title:

    Director, President and Chief Executive Officer

    (Principal Executive Officer)

    ‌


    Get the next $BIOL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BIOLASE Voluntarily Initiates Chapter 11 Proceedings

      LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.The Company also announced today that it is pursuing a sale process under Section 363 of the Bankruptcy Code in conjunction with the filing. To this end, BIOL

      10/1/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

      LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

      8/8/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BIOL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/23/24 4:05:29 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/21/24 4:39:54 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biolase Inc.

      SC 13G - BIOLASE, INC (0000811240) (Subject)

      2/14/24 4:06:57 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Leadership Updates

    Live Leadership Updates

    See more
    • Strateos Appoints Alexander K. Arrow as Chief Financial Officer and Expands Team

      Juliet M. Moritz appointed Vice President, Project Management Office Strateos, Inc., a pioneer in the development of remote access laboratories and lab automation software for life science research, today announced the appointment of Alexander K. Arrow, MD, CFA, as Chief Financial Officer. Dr. Arrow will join the Executive Leadership team and play a key role in leading the company's business and finance strategy focused on growth and new investments. The company has also named Juliet M. Moritz, MPH, Vice President, Project Management Office, reflecting the significant demand by large pharmaceutical companies and contract research organizations for deployment of Strateos Lodestar™ Software.

      2/8/23 8:00:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER

      Dr. Morrow brings extensive clinical, dental and DSO experience to help expand laser adoption globally LAKE FOREST, Calif., Oct. 13, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced the appointment of Russell Morrow, D.D.S. as Chief Dental Officer ("CDO"), effective November 1, 2022. Dr. Samuel Low, who has served as Chief Dental Officer since 2016, will be taking on a new role as Vice President, Clinical Strategic Alliances, where he will focus on building partnerships and growth with Dental Service Organizations (DSOs), universities and government institutions.

      10/13/22 6:30:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • BIOLASE Expands Core Capabilities As It Appoints Three New Board Members With Significant Dental Experience

      FOOTHILL RANCH, Calif., Aug. 16, 2021 /PRNewswire/ -- Demonstrating a deep commitment to expanding the core capabilities and diversity of its Board of Directors, BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced it has appointed three new board members to its Board of Directors (the "Board"), effective immediately. Drs. Kathleen T. O'Loughlin, Carol Gomez Summerhays, and Martha Somerman join a Board that has been instrumental in establishing and implementing the Company's business plan, which has demonstrated significant growth over the past several quarters.

      8/16/21 6:30:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Yale Kenneth P.

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:10:00 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Somerman Martha J. Dds, Phd

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:08:49 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Roper Jess

      4 - BIOLASE, INC (0000811240) (Issuer)

      6/12/23 9:07:19 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Colliers Securities resumed coverage on BIOLASE with a new price target

      Colliers Securities resumed coverage of BIOLASE with a rating of Buy and set a new price target of $1.15

      3/8/21 4:09:02 AM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • Maxim Group reiterated coverage on BIOLASE with a new price target

      Maxim Group reiterated coverage of BIOLASE with a rating of Buy and set a new price target of $2.00 from $1.00 previously

      1/26/21 4:24:15 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    SEC Filings

    See more
    • SEC Form 8-K filed by Biolase Inc.

      8-K - BIOLASE, INC (0000811240) (Filer)

      10/8/24 4:47:14 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • Biolase Inc. filed SEC Form 8-K: Bankruptcy or Receivership

      8-K - BIOLASE, INC (0000811240) (Filer)

      10/1/24 4:05:10 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Biolase Inc.

      8-K - BIOLASE, INC (0000811240) (Filer)

      9/6/24 4:05:08 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care

    $BIOL
    Financials

    Live finance-specific insights

    See more
    • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

      LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

      8/8/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability

      Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and SuccessLAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024.First Quarter Financial HighlightsGenerated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialistsThird strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptionsGross margin was re

      5/13/24 4:05:00 PM ET
      $BIOL
      Medical/Dental Instruments
      Health Care